PDUFA VI: Breakthrough Issues Among FDA Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency and industry also decide to drop research into using social media to enhance post-market safety monitoring.
You may also be interested in...
Breakthrough In Two Pages: FDA Offers Preliminary Advice
Agency now allows sponsors of potential breakthrough therapies to request preliminary advice, but sponsors may not necessarily want to use it.
Real-World Evidence: Efficacy Assessments Await FDA Clarity, Pilot Projects
Greater development and use of real-world evidence, such as pragmatic clinical trials and observational studies, to support regulatory decisions on drug efficacy are limited by regulatory, technical and practical hurdles, stakeholders say.
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.